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Familial dilated cardiomyopathy associated with a novel heterozygous RYR2 early 
truncating variant 
Short Title: Novel RYR2 radical variant in DCM 
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Dilated cardiomyopathy (DCM), characterized by dilation and dysfunction of one or 
both ventricles [1], is the most prevalent form of cardiomyopathy. 30–50% of DCM cases are 
genetically determined [2, 3]. Genetic variants over a number of proteins that affect 
cardiomyocyte function are an important cause of DCM. Up until recently, mutations in the 
Ryanodine receptor 2 (RYR2) gene have been shown to be involved, especially in 
catecholaminergic polymorphic ventricular tachycardia (CPVT) [4], and arrhythmogenic 
cardiomyopathy [3]. Herein, is reported on a family with a novel early truncation in RYR2 
associated with an autosomal-dominant form of DCM.  
A 51-year-old woman of Caucasian descent (Case 1) was admitted to the documented 
hospital for decompensated heart failure (New York Heart Association [NYHA] stage IV). 
Her 12-lead electrocardiogram (ECG) showed sinus rhythm with T-wave inversions (TWI) in 
leads II, III, aVF and V3–V6 (Fig. 1A). The trans-thoracic echocardiography (TTE) showed a 
heavily dilated left ventricle (LV) (LV end diastolic volume index [LVEDVi] 129 mL/m2) 
with a decreased LV ejection fraction (LVEF) of < 15%, in the presence of diffuse 
hypokinesia without evidence of an LV thrombus (Fig. 1B) The left atrium (LA) was 
moderately dilated (LA volume index [LAVI] 45 mL/m2). Magnetic resonance imaging 
(MRI) showed no evidence of fibrosis or fatty infiltration, but confirmed DCM (Fig. 1C) with 
normal right ventricle (RV) dimensions and function. Medical therapy for heart failure was 
started and optimized including lisinopril (5 mg bid), later changed to valsartan (50 mg tid), 
bisoprolol (5 mg bid), spironolactone (25 mg qd), and torasemide (10 mg qd). 48 h Holter-
ECG only showed a very low premature ventricular complex (PVC) burden (0.3%) and no 
tachyarrhythmia, while two exercise stress tests revealed no PVCs or other forms of 
ventricular tachyarrhythmia. Nevertheless, despite being on optimal guideline-directed 
medical therapy at 4 month follow-up, a markedly decreased LVEF on TTE (22%) 
necessitated the implantation of a subcutaneous implantable cardioverter-defibrillator (ICD) 
for primary prevention. The family history indicated a familial autosomal-dominant form of 
DCM: the mother of the index case was transplanted for heart failure due to DCM at the age 
of 45 years, while the mother’s brother died of heart failure due to DCM at the age of 70. No 
genetic tests or tissue were available. During cascade screening, one of the daughters (Case 
2) of the index patient, a 26-year-old woman, was found to have a slightly dilated LV 
(LVEDVi 66 mL/m2) with a normal LVEF (57%). Her 12-lead ECG showed normal sinus 
rhythm and normal de-/repolarization. A 48 h Holter-ECG showed a low PVC burden 
(0.06%) and no tachyarrhythmia. Further investigations revealed late gadolinium 
enhancement (LGE) on cardiac MRI, specifically in the LV apical and septal areas, as well as 
a transmural scar in the inferior LV.  
The genetic test performed in the index patient (Case 1; performed using next 
generation sequencing technology — Illumina’s Trusight Cardio sequencing panel, covering 
176 genes) resulted in a previously unreported variant in Exon 4 of the RYR2 gene 
(heterozygous c.294G>A; p.Trp98Ter), which is considered likely pathogenic (class IV) 
following the 2015 American College of Medical Genetics criteria [5], since it is an early 
truncating variant and leads to a significantly shortened and dysfunctional protein product. 
The same variant was identified through Sanger Sequencing in the phenotypically affected 
daughter (Case 2), while it was not identified in the two other healthy siblings. Recently, 
evidence has been emerging about genes encoding sarcoplasmatic reticulum (SR) proteins as 
putative for DCM [3].  
The cardiac RYR2 is an important calcium (Ca2+) release channel of the SR and plays 
an essential role in excitation-contraction coupling in cardiomyocytes [6]. RYR2 dysfunction 
causes an abnormal Ca2+ leakage from the SR, which can generate delayed 
afterdepolarizations, which in turn can lead to ventricular arrhythmias [7]. RYR2 variants 
altering the termination of Ca2+ release seem to lead to a cardiomyopathic phenotype, which 
is usually associated with mutations in sarcomeric proteins. Specifically, DCM-associated 
sarcomeric variants tend to decrease the myofilament Ca2+ sensitivity and thus increase 
cytosolic Ca2+ transients. The abnormal cytosolic Ca2+ transient resulting from altered 
myofilament Ca2+ sensitivity is thought to trigger cardiac remodeling (via Ca2+/calmodulin-
dependent signaling pathways, the calcineurin/NFAT pathways, or apoptotic signaling) that 
can lead to DCM [8]. Moreover, in dystrophic cardiomyopathy, the RYR hypersensitivity for 
Ca2+ due to redox modifications is not only responsible for excessive stress responses, but 
also changes the signal transduction linking L-type Ca2+ channels to RYRs during excitation-
contraction coupling [9]. This connection between abnormal RYR function and dystrophic 
cardiomyopathy further underlines a putative role for abnormal RYR function not only in 
arrhythmogenesis, but also in cardiomyopathies. 
Genetic variants in the RYR2 gene are frequently autosomal dominant and usually 
associated with CPVT, but radical variants such as truncating variants, have also been 
described in the setting of DCM. There are various studies, where RYR2 variants have been 
recognized as causative in a small number of patients with DCM. In 2007, Bhuiyan et al. [10] 
reported two families with a deletion in exon 3 of the RYR2 gene, displaying a phenotype of 
CPVT in some family members and a DCM phenotype with LV dysfunction in other family 
members. Ohno et al. [6] linked large deletions in Exon 3 of the RYR2 gene to LV non-
compaction cardiomyopathy in two unrelated probands and their affected family members. 
This is in line with the present findings: the variant in this family leads to a stop codon which 
generates an early truncation (exon 4 out of 105 exons), leading to a dysfunctional protein 
product. Together with the, albeit limited, co-segregation shown in the reported family, this 
confirms a putative pathogenic role of the current reported truncating heterozygous RYR2 
genetic variant (c.294G>A; p.Trp98Ter) in the setting of familial DCM. 
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Figure 1. Diagnostic work-up in the index patient. A. 12-lead electrocardiogram showing 
sinus rhythm with T wave inversions in II, III, aVF and V3–V6, and two premature 
ventricular complexes originating from the anterobasal left ventricle (LV); B. Transthoracic 
echocardiogram showing a heavily dilated LV (LV end-diastolic volume index: 129 mL/m2); 
C. Cardiac magnetic resonance imaging, confirming dilated cardiomyopathy without fibrosis 
or fatty infiltration. 
 

